Here, we provide an overview of the link between T2DM, HF and renal insufficiency, and discuss these associations in the context of cardiovascular and renal outcomes with SGLT2 inhibitors in patients with and without T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.